Effect of intermittent subchronic MK ‐801 administration on dopamine synthesis capacity and responsiveness in the prefrontal cortex
Neuropsychopharmacology Reports · 2024
DOI: 10.1002/npr2.12420 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychopharmacology Reports, 2024. Verfasst von Kazuro Shibata und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Dizocilpine Maleate, Prefrontal Cortex, Dopamine, Excitatory Amino Acid Antagonists. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Aim
The therapeutic potential of N‐methyl‐D‐aspartate glutamate receptor (NMDAR) antagonists, particularly ketamine, in mood disorders, is linked to their modulation of dopamine dynamics in the medial prefrontal cortex (mPFC). However, conflicting effects of distinct NMDAR antagonists, like ketamine and phencyclidine, on mPFC dopamine levels stem from variances in their receptor affinity profiles. This study investigates the impact of intermittent subchronic administration of an NMDAR antagonist on dopamine synthesis capacity and responsiveness within the mPFC, focusing on Dizocilpine (MK‐801), a highly selective NMDAR antagonist.
Methods
In vivo microdialysis and high‐performance liquid chromatography assessed extracellular dopamine levels in the mPFC following subchronic MK‐801 treatment. Locomotor activity was measured using a computed video tracking system.
Results
Intermittent subchronic MK‐801 administration, followed by a 24‐h withdrawal, preserved both dopamine synthesis capacity and responsiveness to MK‐801 challenge in the mPFC. However, altered locomotor activity was observed, deviating from previous findings indicating impaired dopamine synthesis and responsiveness in the mPFC with twice‐daily subchronic NMDAR antagonist treatment.
Conclusion
These findings offer crucial biochemical insights into the diverse impacts of NMDAR antagonists on dopamine dynamics and the distinct therapeutic mechanisms associated with ketamine in depression treatment. However, further investigation is imperative to pinpoint potential inconsistencies stemming from variances in drug type, dosage, or administration frequency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan.
- Department of Psychiatry, Kitasato University, Sagamihara-Shi, Kanagawa, Japan.
- Miyakonojo Shinsei Hospital, Miyakonojo-shi, Miyazaki, Japan.
- CNS Pharmacological Research Institute, Shibuya-ku, Tokyo, Japan.
ORCID-Profile: Kazuro Shibata, Ken Inada, Katsuji Nishimura, Hidehiro Oshibuchi
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Shibata, K., Enomoto, K., Tsutsumi, T., Muraoka, H., Fuwa, T., Kawano, M., Ishigooka, J., Inada, K., Nishimura, K., & Oshibuchi, H. (2024). Effect of intermittent subchronic MK ‐801 administration on dopamine synthesis capacity and responsiveness in the prefrontal cortex. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.12420
Vancouver
Shibata K, Enomoto K, Tsutsumi T, Muraoka H, Fuwa T, Kawano M, et al. Effect of intermittent subchronic MK ‐801 administration on dopamine synthesis capacity and responsiveness in the prefrontal cortex. Neuropsychopharmacology Reports. 2024. doi:10.1002/npr2.12420
BibTeX
@article{Shibata2024,
author = {Shibata, Kazuro and Enomoto, Kosuke and Tsutsumi, Takahiro and Muraoka, Hiroyuki and Fuwa, Tatsu and Kawano, Masahiko and Ishigooka, Jun and Inada, Ken and Nishimura, Katsuji and Oshibuchi, Hidehiro},
title = {Effect of intermittent subchronic MK ‐801 administration on dopamine synthesis capacity and responsiveness in the prefrontal cortex},
journal = {Neuropsychopharmacology Reports},
year = {2024},
doi = {10.1002/npr2.12420}
}
EUVIMED